Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that the Company will be participating in two upcoming investor conferences:
- Oppenheimer’s 32 nd Annual Healthcare Conference: On March 17, 2022 at 12:40pm ET, Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215.
- Guggenheim Healthcare Talks, 2022 Genomic Medicines and Rare Disease: Astria Therapeutics will be participating in the conference, which will take place on March 31 and April 1, 2022.
A live webcast of the Oppenheimer presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer20/atxs/2810304 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com , or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005065/en/
Astria Contacts:
Investor relations:
Andrea Matthews
investors@astriatx.com
Media:
Elizabeth Higgins
media@astriatx.com